PHARMACIELO LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.15 CAD | -3.23% |
|
-16.67% | -16.67% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Capitalization 1 | 298.4 | 288.6 | 145.8 | 26.5 |
| Enterprise Value (EV) 2 | 286.2 | 283.4 | 148.6 | 38.76 |
| P/E ratio | -8.45 x | -5.35 x | -5.36 x | -1.82 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 379,166,270 x | 108,736,035 x | 74,957,814 x | 4,991,428 x |
| EV / Revenue | 363,653,706 x | 106,800,522 x | 76,397,769 x | 7,301,159 x |
| EV / EBITDA | -9.23 x | -9.11 x | -5.95 x | -3.62 x |
| EV / FCF | 16,835,796 x | -44,562,323 x | -10,279,871 x | -5,841,501 x |
| FCF Yield | 0% | -0% | -0% | -0% |
| Price to Book | 6.64 x | 11 x | 7.57 x | 4.24 x |
| Nbr of stocks (in thousands) | 97,825 | 138,739 | 148,768 | 151,412 |
| Reference price 3 | 3.050 | 2.080 | 0.9800 | 0.1750 |
| Announcement Date | 4/29/20 | 5/3/21 | 4/29/22 | 5/1/23 |
1CAD in Million2USD in Million3CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 0.7869 | 2.654 | 1.945 | 5.309 |
| EBITDA 1 | -12.06 | -23.24 | -31.02 | -31.12 | -24.96 | -10.7 |
| EBIT 1 | -12.7 | -23.89 | -31.9 | -31.95 | -25.06 | -11.08 |
| Operating Margin | - | - | -4,053.39% | -1,204% | -1,288.29% | -208.69% |
| Earnings before Tax (EBT) 1 | -13.03 | -24.42 | -34.67 | -43.76 | -26.63 | -14.52 |
| Net income 1 | -13.03 | -24.43 | -34.67 | -43.76 | -26.63 | -14.52 |
| Net margin | - | - | -4,405.55% | -1,648.73% | -1,369.14% | -273.45% |
| EPS 2 | -0.1771 | -0.3124 | -0.3609 | -0.3888 | -0.1828 | -0.0961 |
| Free Cash Flow | - | -31.67 | 17 | -6.361 | -14.45 | -6.635 |
| FCF margin | - | - | 2,160% | -239.67% | -743.18% | -124.99% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 1/9/19 | 4/18/19 | 4/29/20 | 5/3/21 | 4/29/22 | 5/1/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 2.8 | 12.3 |
| Net Cash position 1 | 12.8 | 5.66 | 12.2 | 5.14 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.1122 x | -1.146 x |
| Free Cash Flow | - | -31.7 | 17 | -6.36 | -14.5 | -6.63 |
| ROE (net income / shareholders' equity) | -50.7% | -70.1% | -63.8% | -122% | -117% | -113% |
| ROA (Net income/ Total Assets) | -28.5% | -40.6% | -34.2% | -42.4% | -39.2% | -22.7% |
| Assets 1 | 45.71 | 60.15 | 101.3 | 103.2 | 68 | 64.02 |
| Book Value Per Share 2 | 0.3100 | 0.5700 | 0.4600 | 0.1900 | 0.1300 | 0.0400 |
| Cash Flow per Share 2 | 0.1700 | 0.0700 | 0.1400 | 0.0600 | 0.0400 | 0 |
| Capex 1 | 2.41 | 4.07 | 10.1 | 5.43 | 1.14 | 0.52 |
| Capex / Sales | - | - | 1,277.94% | 204.75% | 58.51% | 9.83% |
| Announcement Date | 1/9/19 | 4/18/19 | 4/29/20 | 5/3/21 | 4/29/22 | 5/1/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -16.67% | 18.6M | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| +0.09% | 1.65B | |
| -7.89% | 1.68B | |
| -12.97% | 1.53B | |
| +33.40% | 1.38B |
- Stock Market
- Equities
- PCLO Stock
- Financials PharmaCielo Ltd.
